Clinical Research Directory
Browse clinical research sites, groups, and studies.
Toludesvenlafaxine for Non-specific Low Back Pain
Sponsor: Beijing Tiantan Hospital
Summary
Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.
Official title: Efficacy and Safety of Toludesvenlafaxine in the Treatment of Non-specific Low Back Pain
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2026-07-15
Completion Date
2028-12-01
Last Updated
2026-07-27
Healthy Volunteers
No
Conditions
Interventions
Active Comparator #1
Participants in the control group will receive routine clinical care for chronic nonspecific low back pain.
Toludesvenlafaxine
Participants in the toludesvenlafaxine group will receive oral toludesvenlafaxine in addition to background care. Toludesvenlafaxine will be administered at 80 mg once daily. For participants with insufficient pain relief and acceptable tolerability, the dose may be cautiously increased to 160 mg once daily. The maintenance treatment period will be 3 months.
Locations (1)
Fang Luo
Beijing, China